title: Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic HSCT needs to be addressed. Similarly, the optimal use of these disease-modifying agents before HSCT needs to be determined. In severe aplastic anemia, HSCT is a proven cure, but HLA-matched sibling donors are found in fewer than 25% of newly diagnosed patients. The use of early unrelated donor HSCT is an evolving concept that will become more accepted as improvements in HSCT outcomes continue.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
authors.forename: Corey
authors.initials: C
authors.lastname: Cutler
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous